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3• ‘Allo’ CTs: Product-driven business model
• Unique manufacturing & supply chain issues:
– Limited large-scale bioprocessing options
– Adherent culture, cells from healthy donors
– Serum-containing cell culture media
– Single-use technologies essential
– Poorly automated, labour-intensive, open
– Fresh / cryo products
– Costly cold-chain transportation
– Point-of-use care
Challenges for Allo Cell Therapy (CT) Manufacture
Image source: Lonza
How can cell therapies
achieve the manufacturing success of
protein biopharmaceuticals?
• Several CT failures attributed to manufacturing*:
- High cost of goods (COG), process variability, loss
of clinical efficacy upon scale-up, inadequate
characterisation
*Source: Brandenberger et al, Bioprocess Intnl, March 2011 Supplement
USP Challenges for Cell Therapy Manufacture
mAbs Cell therapies (MSCs)
Technologies used in
clinical / commercial
batches
Bioreactors 10-layer vessels
Scale required
@ max. demand
6 x 10,000 L SS
6 x 2,000 L SUB
100,000 (!)
x 10-layer vessels
But can only handle 50-100
x 10-layer vessels / batch
Dose per admin 100-2000 mg 100 K – 1 B cells
Annual demand 100-1000 kg 1 B – 100 T cells
Cell culture yield 1-5 g/L 25,000 cells / cm2
Aim: Create a decisional tool to identify the optimal technologies for commercial cell
therapy bioprocesses and the technical innovation required to realize their potential
Demand Process /Facility/Cost parametersTechnology optionsCell type
Optimal USP & DSP strategy for each demand
COG/dose & COG breakdowns
Decisional Tool
Decisional Tool For Cell Therapy Manufacture
Decisional tool integrated:
•Process economics
•Optimisation
•Visualisation
Case study scope:
•Allogeneic manufacture
•Optimal USP & DSP kits
•Current technology gaps
•Performance targets
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6Case Studies: Cell Therapy Bioprocess Economics
Allogeneic single-use volume reduction decisions
(Hassan et al, 2015)
 Scenario: New build for commercial allogeneic cell therapy manufacture
 Impact of dose, demand, lot size on optimal DSP technology
Allogeneic single-use cell expansion decisions
(Simaria et al, 2014)
 Scenario: New build for commercial allogeneic cell therapy manufacture
 Impact of dose, demand, lot size on optimal USP technology
Process change impact on drug lifecycle costs
(Hassan et al, 2016)
 Scenario: Switching from planar to microcarrier technology
 Impact of timing of switch and drug development costs on ranking of strategies
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Allogeneic single-use cell expansion decisions
(Simaria et al, 2014)
 Scenario: New build for commercial allogeneic cell therapy manufacture
 Impact of dose, demand, lot size on optimal USP technology
• Candidate cell expansion technologies:
T-flasks (T) Multi-layers (L) Compact
multi-layers (cL)
Multi-layer
bioreactors (bL)
Hollow fibre
bioreactors (HF)
Microcarriers in
SUBs (M)
Dose: 106-109 cells
Demand: [1,000-500,000] doses/year
Lot size: [50-10,000] doses/lot
Max nr technology units/lot = 80
Max nr SUBs/lot=8
Lot size (#doses/lot)
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Nr lots/year
< 10 lots/year
> 200 lots/year
Case study setup
Case study: Allogeneic cell expansion decisions
Question:
What is the most cost-effective cell
expansion technology for each
demand-lot size combination?
Optimal technologies:
Tool identified where
• planar technologies cease
to be feasible
• microcarrier-SUBs become
the only option
Gap at higher doses:
Current cells/ml value does
not allow making 1013
cells/lot
Case study: Allogeneic cell expansion decisions
Results: optimal technologies across demand/lot size matrix and dose
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Lot size (doses/lot)
Dose=106 cells
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Lot size (doses/lot)
Dose=107 cells
9Simaria, Hassan, Varadaraju, Rowley, Warren, Vanek, Farid. 2014. Biotechnol. Bioeng. 111(1) 69-83
Here, the use of microcarriers was allowed only when the maximum number of units was exceeded for all planar technologies.
Case study: Allogeneic cell expansion decisions
Technology S-curve for cell therapy manufacture
S-curve illustrates performance limits of each technology
TARGET: 10,000 BILLION CELLS PER LOT
(eg lot size=10,000 doses, dose=109 cells)
Microcarrier-SUBs
require x2 increase in
performance for high
demand scenarios
Planar capacity capped
at ~500B cells/lot
(MSCs)
Technology Gap:
Simaria, Hassan, Varadaraju, Rowley, Warren, Vanek, Farid. 2014. Biotechnol. Bioeng. 111(1) 69-83
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Case Studies: Cell Therapy Bioprocess Economics
Allogeneic single-use volume reduction decisions
(Hassan et al, 2015)
 Scenario: New build for commercial allogeneic cell therapy manufacture
 Impact of dose, demand, lot size on optimal DSP technology
• To meet max. demand need 25,000 benchtop centrifuges!
DSP Challenges for Cell Therapy Manufacture
• Current volume reduction processes typically use:
• Benchtop centrifuges
• Quantities of cells required for commercial products:
• Doses: 105 – 109 cells/patient
• Potential market demands: 10,000 – 500,000 patients /yr
• Annual cell demand: 109 – 1014 cells/yr
• Cells per lot: 108 – 1013 cells/lot
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Candidate Volume Reduction Technologies:
Fluidised bed centrifugation
(FBC)
Tangential flow filtration
(TFF)
Case Study: Allogeneic DSP Decisions
TFF membrane area 0.02 - 1.15m2 FBC chamber volume 1-4 x 100ml chambers
1-6 x 1000ml chambers
Max nr volume reduction units/lot =1
Max volume reduction time = 4 h
Target concentration: 10 M cells/ml
Question:
What is the most cost-effective cell volume reduction technology for each demand-lot size
combination?
13Hassan, Simaria, Varadaraju, Gupta, Warren, Farid.. 2015. Regen Med 10 (5), 591-609.
Gap at higher doses:
For large lot sizes bottleneck
hits DSP before USP
For microcarrier-SUBs, no
DSP technology meets limit
on number of units without
debottlenecking efforts
Case study: Allogeneic DSP decisions
Results: optimal technologies across demand/lot size matrix and dose
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DSP
bottleneck
Hassan, Simaria, Varadaraju, Gupta, Warren, Farid.. 2015. Regen Med 10 (5), 591-609.
• Typical biologics COG = 15% sales
• Assumption: cell therapies will have similar gross margins to biologics
Case study: Allogeneic process decisions
Cost of goods as %sales
*Assumption: reimbursement value of $40K/dose @dose=109cells, 50 doses/lot, demand = 10,000 doses/y
15Simaria et al., 2014. Biotechnol Bioeng; Hassan et al. 2015. Regen Med
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Case Studies: Cell Therapy Bioprocess Economics
Process change impact on drug lifecycle costs
(Hassan et al, 2016)
 Scenario: Switching from planar to microcarrier technology
 Impact of timing of switch and drug development costs on ranking of strategies
Case study: Process change decisions
Planar v Microcarriers: COST OF DEVT v COG savings
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PL = planar technology
MC = microcarriers in SUBs
Cell type: MSCs. Example dose: 2 x 108 cells
Will the COG savings
outweigh the COST OF DEVT?
Microcarriers: 45-75% COG savings
(Commercial scale)
Hassan, Huang, Warren, Mahdavi, Smith, Jong, Farid. 2016. Regen Med 11(3), 287-305
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• In all cases DSP includes TFF and cryopreservation.
• Each switch to MC-SUB involves parallel arm with cell factory equivalent.
• CF = Cell Factory, MC-SUB = Microcarrier in SUB
Phase I Phase II Phase III Market
Planar technologies throughout PL CF-10 CF-10 CF-40 CF-40
Change to MC-SUB post-approval MC-PA CF-10 CF-10 CF-40 MC-SUB
Change to MC-SUB at Phase III MC-P3 CF-10 CF-10 MC-SUB MC-SUB
Change to MC-SUB at Phase II MC-P2 CF-10 MC-SUB MC-SUB MC-SUB
MC-SUB throughout MC-P1 MC-SUB MC-SUB MC-SUB MC-SUB
Case study: Process change decisions
Technologies used in each phase and case
 Scenario: Switching from planar to microcarrier technology
 Impact of timing of switch and drug development costs on ranking of strategies
Hassan, Huang, Warren, Mahdavi, Smith, Jong, Farid. 2016. Regen Med 11(3), 287-305
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Case study: Process change decisions
Process Change Lifecycle Cash Flow Model
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KEY OUTPUTS:
Lifecycle Costs
Reimbursement
Profitability
Hassan, Huang, Warren, Mahdavi, Smith, Jong, Farid. 2016. Regen Med 11(3), 287-305
DRUG DEVT PERSPECTIVE:
• Switch to MC-SUB early best
• Switch to MC-SUB post-approval worst
Case study: Process change decisions
Results: Total phase costs and profitability for each process change case
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COST OF DEVT PROFITABILITY
DRUG LIFECYCLE PERSPECTIVE:
• Switch to MC-SUB post approval best
• Sticking to planar worst
Hassan, Huang, Warren, Mahdavi, Smith, Jong, Farid. 2016. Regen Med 11(3), 287-305
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% change in COST OF DEVT for MC-SUBs
SWITCH TO
MICROCARRIERS WINS
PLANAR WINS
If COG difference is high (eg -50%)
SWITCH TO MICROCARRIERS wins
irrespective of COST OF DEVT
If COG difference is low (eg -25%)
SWITCH TO MICROCARRIERS
depends on COST OF DEVT
Case study: Process change decisions
Results: Impact of COST OF DEVT v COG savings on PROFITBAILITY
Market: 10,000 patients/y
Will switching to microcarriers post
approval always beat sticking to
planar?
Hassan, Huang, Warren, Mahdavi, Smith, Jong, Farid. 2016. Regen Med 11(3), 287-305
Summary
Cell therapy candidate in early phase development with:
• Early clinical data
- e.g. cell type, dose estimate, patient numbers
• Early process data
- e.g. yields
UCL Decisional Tools outputs can be used to help with decision-making:
 Compare the cost-effectiveness of alternative manufacturing processes / supply chains
 Identify the most cost-effective and GMP-ready process for
 current scale of operation
 future scales for late phase / commercial manufacture
 Predict and manage the risk of process changes as products proceed through
development pathway
 Identify most promising technologies and targets to reach for future R&D investment
Cell therapy company
UCL Decisional Tools researchers
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Decisional Tools industry collaborators include: Lonza, Pall, Pfizer, GSK s.farid@ucl.ac.uk
Allogeneic MSCs
Process change evaluation framework for allogeneic cell therapies: impact on drug development and
commercialization. Hassan S, Huang H, Warren K, Mahdavi B, Smith D, Jong S, Farid SS. 2016.
Regenerative Medicine, 11(3), 287-305. DOI 10.2217/rme-2015-0034
Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.
Hassan S, Simaria AS, Varadaraju H, Gupta S, Warren K, Farid SS. 2015. Regenerative Medicine 10 (5),
591-609. DOI 10.2217/rme.15.29
Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.
Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K, Vanek P, Farid SS. 2014. Biotechnology &
Bioengineering 111(1) 69-83.
iPSCs
Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation.
Jenkins, M.J., Bilsland, J., Allsopp, T.A., Ho, S.V., Farid, S.S. 2016. Biochemical Engineering Journal,
108, 84–97. DOI 10.1016/j.bej.2015.09.024
Human pluripotent stem cell-derived products: Advances towards robust, scalable and cost-effective
manufacturing strategies. Jenkins MJ, Farid SS. 2015. Biotechnology Journal. 10, 83–95. DOI
10.1002/biot.201400348
CAR T-cells and RPE cells
Tania Chilima et al & Michael Jenkins et al coming soon…
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